# A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine

> **NCT02606084** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 32 (actual)

## Conditions studied

- Renal Impairment
- Healthy

## Interventions

- **DRUG:** Esketamine

## Key facts

- **NCT ID:** NCT02606084
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-04
- **Primary completion:** 2018-02-02
- **Final completion:** 2018-02-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02606084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02606084, "A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02606084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*